Page last updated: 2024-12-05

trifluridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6256
CHEMBL ID1129
CHEBI ID75179
SCHEMBL ID3479
MeSH IDM0021960

Synonyms (130)

Synonym
MLS001148248
SRI-10817-12
5-trifluoromethyl-2-deoxyuridine
nsc-529182
tfdu
5-(trifluoromethyl)deoxyuridine
2'-deoxy-5-(trifluoromethyl)uridine
trifluoromethyldeoxyuridine
2'-deoxy-5-trifluoromethyluridine
trifluorothymidine ,
f3dthd
smr000058583
MLS000028361 ,
cf3durd
nsc-75520
viroptic
f3t
fluridine
trifluridine
nsc75520
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
nsc529182
virophta
f3tdr
uridine, 2'-deoxy-5-(trifluoromethyl)-
5-(trifluoromethyl)-2'-deoxyuridine
70-00-8
trifluorothymidine, >=99% (hplc)
DB00432
trifluorothymine deoxyriboside
D00391
trifluridine (jan/usp/inn)
viroptic (tn)
5-trifluoro-2'-deoxythymidine
5-trifluorothymidine
nsc 75520
trifluridinum [inn-latin]
thymidine, alpha,alpha,alpha-trifluoro-
brn 0568095
nsc 529182
trifluridina [inn-spanish]
einecs 200-722-8
ccris 2348
2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-beta-d-ribofuranosyl)-5-(trifluoromethyl)-
5-trifluoromethyl-2'-deoxyuridine
T2511
alpha,alpha,alpha-trifluorothymidine
bdbm50132298
1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1h,3h)-dione
trifluoromethyl deoxyuridine
cid_6708818
cid_6256
5-trifluoromethyl-2''-deoxyuridine
1-((2r,5r)-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-trifluoromethyl-1h-pyrimidine-2,4-dione
chebi:75179 ,
CHEMBL1129 ,
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
A836733
BRD-K03243820-001-12-1
5 trifluoromethyl 2' deoxyuridine
tox21_112411
dtxcid2026602
dtxsid4046602 ,
AKOS015919482
HMS2233N19
5-trifluoromethylthymidine
trifluridina
hsdb 8126
trifluridine [usan:usp:inn]
unii-rmw9v5rw38
trifluridinum
rmw9v5rw38 ,
AM20100660
trifluridine [mart.]
trifluridine [mi]
trifluridine [orange book]
trifluridine [usp monograph]
trifluridine [ep monograph]
s-95005 component trifluridine
thymidine, .alpha.,.alpha.,.alpha.-trifluoro-
trifluridine [usp-rs]
trifluridine [who-dd]
tas-102 component trifluridine
trifluridine [jan]
trifluridine [inn]
trifluridine [usan]
trifluridine component of lonsurf
trifluridine [vandf]
CCG-221056
HY-A0061
CS-1602
MLS006010219
1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
SCHEMBL3479
NCGC00166323-02
tox21_112411_1
HS-0007 ,
J-700255
J-700357
1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1h,3h)-dione
trifluridine, british pharmacopoeia (bp) reference standard
gtpl8697
OPERA_ID_1810
SRI-10817_14
mfcd00006534
SR-01000721911-2
sr-01000721911
trifluridine, united states pharmacopeia (usp) reference standard
HMS3715C14
SW199522-2
trifluridine;ftd;5-trifluorothymidine;nsc 529182;nsc 75520
trifluridine (viroptic)
S1778
BCP09147
Q2359590
BRD-K03243820-001-25-3
NCGC00166323-16
EN300-24409722
trifluridinum (latin)
s01ad02
trifluridine (ep monograph)
triflorothymidine
trifluridine (usan:usp:inn)
trifluridine (usp monograph)
trifluridine (mart.)
trifluridine (usp-rs)
trifluridinum (inn-latin)
trifluridina (inn-spanish)
trifluridin
BP-58659

Research Excerpts

Overview

Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI) inhibits the rapid degradation of FTD. Trif luridine/tipiracil is a treatment used in refractory metastatic digestive cancers.

ExcerptReferenceRelevance
"Trifluridine/tipiracil is a compound drug, approved in 2015 by the US FDA, and in 2016 by the EMA, for the treatment of chemorefractory metastatic colorectal cancers, after the phase III RECOURSE trial demonstrated significant benefit. "( Trifluridine/tipiracil in the treatment of gastric cancer.
Arkenau, HT; Fostea, RM, 2022
)
3.61
"Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC."( Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S, 2023
)
1.86
"Trifluridine/tipiracil is a treatment used in refractory metastatic digestive cancers."( IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report.
Brochériou, I; Desbuissons, G; Fournier, P; Ngango, L, 2020
)
1.56
"Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI) inhibits the rapid degradation of FTD. "( Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Barzi, A; Berger, MD; Borelli, B; Cao, S; Dadduzio, V; Gopez, R; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Pietrantonio, F; Salvatore, L; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W, 2017
)
1.9
"Trifluridine (FTD) is an active cytotoxic component of TFTD and mediates the anticancer effect via its incorporation into DNA."( Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.
Iimori, M; Kiniwa, M; Kitao, H; Kurashige, J; Maehara, Y; Morodomi, Y; Nakanishi, R; Nakashima, Y; Oki, E; Saeki, H; Sugiyama, M, 2017
)
1.57
"Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer."( Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J, 2018
)
2.64
"Trifluridine (FTD) is a key component of the novel oral antitumor drug trifluridine/tipiracil that has been approved for the treatment of metastatic colorectal cancer. "( ChIP-seq Analysis to Explore DNA Replication Profile in Trifluridine-treated Human Colorectal Cancer Cells
Kobunai, T; Matsuoka, K; Takechi, T, 2019
)
2.2
"Trifluridine-tipiracil is an oral antineoplastic agent consisting of trifluridine (a trifluorothymidine, a thymidine-based nucleoside analog) and tipiracil (a thymidine phosphorylase inhibitor), at a molar ratio of 1:0.5. "( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
2.25
"Trifluridine-tipiracil is a new treatment option for patients with mCRC who have received at least 2 prior lines of standard chemotherapy (including fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and an antiepidermal growth factor receptor antibody in patients with KRAS wild-type tumors). "( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
2.25
"Trifluridine (FTD) is a key component of the novel oral antitumor drug TAS-102, which consists of FTD and a thymidine phosphorylase inhibitor. "( Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.
Ando, K; Iimori, M; Kiniwa, M; Kitao, H; Kiyonari, S; Maehara, Y; Matsuoka, K; Niimi, S; Oki, E; Saeki, H; Tokunaga, E; Tsukihara, H; Watanabe, S, 2015
)
3.3
"Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor). "( Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.
Chiba, M; Komoto, I; Kuwata, K; Nakagawa, F; Oka, H; Takeuchi, M; Yamashita, F; Yoshisue, K, 2015
)
2.13
"Trifluridine (FTD) is a key component of the novel oral antitumor drug TAS-102 (also named TFTD), which consists of FTD and a thymidine phosphorylase inhibitor. "( The antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA.
Iimori, M; Kataoka, Y; Kiniwa, M; Kitao, H; Maehara, Y; Matsuoka, K; Morodomi, Y; Niimi, S; Oki, E; Saeki, H; Shigeno, K; Tokunaga, E, 2016
)
2.11

Effects

Trifluridine/tipiracil has been approved for the treatment of refractory metastatic colorectal cancer. It can be considered in patients with prior intolerance or toxicity to 5-FU.

ExcerptReferenceRelevance
"Trifluridine/tipiracil has activity in patients with 5-FU-resistant tumors and can be considered in patients with prior intolerance or toxicity to 5-FU."( Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
Burge, M; Chantrill, L; Gibbs, P; Pavlakis, N; Price, T; Shapiro, J; Sjoquist, K, 2020
)
2.72
"Trifluridine/tipiracil has been approved for the treatment of refractory metastatic colorectal cancer. "( Leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura after trifluridine/tipiracil treatment.
Aria, AB; Chen, L; Chon, SY; Glass, WF; Lahoti, A, 2018
)
2.15
"Trifluridine/tipiracil has recently been approved for the treatment of adult patients with metastatic colorectal cancer (mCRC) who are refractory to or are not considered candidates for, current standard chemotherapy and biological therapy in the EU and USA and in unresectable advanced or recurrent CRC in Japan."( Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Burness, CB; Duggan, ST, 2016
)
2.6

Treatment

ExcerptReferenceRelevance
"Trifluridine treatment was highly effective in this rabbit model, even when given only once a day. "( Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis.
Kaufman, HE; Thompson, HW; Varnell, ED, 1998
)
3.19

Toxicity

The most common grade ≥ 3 adverse events in trifluridine-tipiracil groups in Phase II and III trials were neutropenia, anemia, and leukopenia.

ExcerptReferenceRelevance
"The present paper reviews the adverse side effects caused by topically applied antiviral agents in herpetic keratitis."( [Adverse side effects caused by topically applied antiviral agents in herpetic keratitis].
Chen, CW, 1989
)
0.28
"1 mL of vidarabine can be combined for intravitreal injection without toxic retinal effects."( Retinal toxicity of combination antiviral drugs in an animal model.
Fiscella, R; Peyman, GA; Small, GH; Smith, RT; Srinivasan, A, 1987
)
0.27
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" However, the manufacturer has requested healthcare professionals to help develop safety measures for the appropriate and safe use of the tablets."( [Initial Evaluation of the Efficacy and Safety of Tablets Containing Trifluridine and Tipiracil Hydrochloride--Safety Measures Devised by a Multidisciplinary Team Including a Pharmaceutical Outpatient Clinic].
Aimono, Y; Aoyama, Y; Kamoshida, T; Maruyama, T; Nemoto, M; Saito, Y; Sakamoto, R, 2015
)
0.65
" The most common grade 3 or 4 adverse events were neutropenia (41."( Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T, 2016
)
0.74
" Major adverse events were neutropenia, leukopenia, anemia, and nausea."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
" The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%)."( Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Kusaba, H; Makiyama, A; Matsushita, Y; Mitsugi, K; Shibata, Y; Shimokawa, HK; Shirakawa, T; Tamura, S, 2016
)
0.43
" Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95."( Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016
)
0.71
" This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs) of TAS-102 in clinical practice in the first 6 months after market launch."( TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.
Fujita, N; Furuta, T; Hara, N; Katori, J; Muro, K; Uetake, H; Yoshino, T, 2016
)
0.43
" Drug-related adverse events (AEs) and grade ≥3 AEs were 23 (100%) and 10 (43."( Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016
)
0.43
" Integrated data from a larger group of mCRC patients receiving trifluridine/tipiracil at the recommended starting dose (group 1) and nonintegrated data on serious adverse events (SAEs) representing all clinical experience with trifluridine/tipiracil as of the data cutoff date (group 3) are also summarized."( Integrated safety summary for trifluridine/tipiracil (TAS-102).
Bebeau, P; Bendell, JC; Buscaglia, M; Falcone, A; Kopetz, S; Mayer, RJ; Ohtsu, A; Van Cutsem, E; Yoshino, T, 2018
)
1.01
" This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate."( Fluoropyrimidine-induced cardiotoxicity.
Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018
)
0.48
" The Grade 3 or worst adverse event that was experienced was neutropenia."( [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa, S; Asano, Y; Horiguchi, A; Imaeda, Y; Isetani, M; Ishihara, S; Ito, M; Ito, R; Kamio, K; Kawabe, N; Kawai, T; Nagata, H; Shimizu, K; Tomishige, H; Yasuoka, H, 2018
)
0.48
" Overall, no adverse events other than neutropenia were noted."( Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer.
Narihiro, S; Ohtsu, M; Okamoto, T; Ryu, S; Shimoyama, Y; Suwa, K; Ushigome, T; Yanaga, K,
)
0.44
"5% of patients (n = 101), 253 adverse events (AE) were documented, most of them drug-related (n = 135)."( Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A, 2018
)
0.81
"0%) had at least 1 adverse event leading to study discontinuation."( Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019
)
0.81
"1% both) were the most frequent adverse events."( Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020
)
0.87
" The most common grade ≥ 3 adverse events in trifluridine-tipiracil groups in Phase II and III trials were neutropenia, anemia, and leukopenia."( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
1.07
" Among FTD/TPI-treated patients, grade 3 or higher adverse events of any cause occurred in 122 of 145 patients (84."( Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E, 2020
)
0.87
" Fruquintinib exhibited better PFS, good tolerability and reduced gastrointestinal adverse effects in wild-type KRAS subgroup, making it a promising agent to treat patients with wild-type KRAS mCRC beyond the second line."( Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Cao, M; Zhang, J; Zhou, M, 2020
)
0.56
" Adverse events (AEs) were experienced by 96."( Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Atlan, D; Bachet, JB; Becquart, M; Cicin, I; Cremolini, C; Falcone, A; Mounedji, N; Ozet, A; Phelip, JM; Portales, F; Price, T; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L, 2020
)
0.81
" Overall survival (OS) and adverse events were compared between the groups."( Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Kawakami, K; Nakashima, M; Takeuchi, M, 2020
)
0.82
" The incidences of most adverse events were the lowest in the TFTD group."( Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Kawakami, K; Nakashima, M; Takeuchi, M, 2020
)
0.82
" Common treatment-related adverse events of grade 3 or worse were neutrophil count decreased (27 [82%] in cohort A and 23 [74%] in cohort B), white blood cell count decreased (eight [24%] and seven [23%]), and platelet count decreased (eight [24%] and four [13%])."( Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Amagai, K; Ando, T; Fujita, J; Fujitani, K; Hosaka, H; Kawazoe, A; Koeda, K; Nishikawa, K; Ogata, K; Shitara, K; Watanabe, K; Yamamoto, Y, 2021
)
0.93
" Although the incidence of hematological toxicity in the elderly patient group was higher than that in the younger patient group, there were no significant differences in the rate of treatment discontinuation due to adverse events between the two groups."( The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
En, W; Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Ohira, M; Okazaki, Y; Shibutani, M, 2021
)
0.92
" Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]."( Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A, 2022
)
1.03
" The most frequent treatment-emergent adverse events were neutropenia (27."( Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
Ettrich, TJ; Heinemann, V; Hess, J; Karthaus, M; Klein, A; Kretzschmar, A; Pelz, H; Reisländer, T; Riera-Knorrenschild, J; Vehling-Kaiser, U; Weiss, L; Welslau, M, 2022
)
0.93
" Adverse events of any grade were reported in 58% of patients."( Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022
)
1
" The primary endpoints were dose-limiting toxicities (DLTs) in Cycle 1 as well as serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) throughout the study; secondary endpoints were pharmacodynamics parameters, objective tumor response, and urinary pharmacodynamics markers of target inhibition."( Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023
)
1.12
" Drug-related grade ≥ 3 adverse events included neutropenia (38."( Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
Bachet, JB; Chevallier, B; Price, T; Taieb, J; Vidot, L; Wyrwicz, L, 2023
)
1.22
" Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13."( Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023
)
1.17
" In the overall population, the most common grade 3 or higher treatment-related adverse events were neutropenia (37%), anemia (32%) leukopenia (20%), thrombocytopenia (8%), and anorexia (7%)."( Safety and Efficacy of Trifluridine/Tipiracil Administered After Anti-PD-1 Therapies for Advanced Gastric Cancer.
Demachi, K; Kawazoe, A; Kotani, D; Nakamura, H; Okunaka, M; Shitara, K,
)
0.44
" No unexpected adverse events were observed in both groups."( Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K, 2023
)
1.22

Pharmacokinetics

ExcerptReferenceRelevance
"To determine the half-life and vitreous clearance of trifluorothymidine, a drug that demonstrates good toxicity against cytomegalovirus (CMV), we injected 200 micrograms of the drug intravitreally in the eyes of nine New Zealand white rabbits."( Half-life and vitreous clearance of trifluorothymidine after intravitreal injection in the rabbit eye.
Blatt, H; Branchflower, RV; Chang, AT; Minatoya, HK; Pang, MP; Peyman, GA, 1992
)
0.28
" In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI."( Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K, 2004
)
0.32
"The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)."( Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006
)
0.33
"The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies."( The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007
)
0.34
" Patients were given single doses of TAS-102 (35 mg/m(2) ) in the pharmacokinetic phase and received twice-daily doses of TAS-102 in 28-day cycles in the repeated administration phase for evaluating efficacy and safety."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43

Compound-Compound Interactions

TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI) The study examined the anti-herpetic effect of the glycoprotein inhibitors, hydroxynorvaline and 2-deoxyglucose on murine ocular herpes.

ExcerptReferenceRelevance
"A phase II trial of pyrazofurin, alone and in combination with trifluorothymidine, was carried out in patients with advanced non-Hodgkin's lymphoma."( Phase II trial of pyrazofurin, alone and in combination with trifluorothymidine, in non-Hodgkin's lymphoma.
Currie, V; Kempin, S; Warrell, RP; Young, C, 1979
)
0.26
" Using a rabbit model, the effects of trifluridine (F3TdR) on corneal edema and stromal disease were examined when combined with each of three immunosuppressive agents."( Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents.
O'Brien, WJ; Taylor, JL, 1991
)
0.79
"The present study examined the anti-herpetic effect of the glycoprotein inhibitors, hydroxynorvaline and 2-deoxyglucose, alone and in combination with trifluridine on murine ocular herpes."( Efficacy of glycoprotein inhibitors alone and in combination with trifluridine in the treatment of murine herpetic keratitis.
Araullo-Cruz, T; Blough, HA; Cheng, KP; Gordon, YJ; Johnson, BJ; Romanowski, E, 1986
)
0.71
" The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated."( Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.
Kelley, E; Spector, SA; Tyndall, M, 1982
)
0.26
"The sensitivity of varicella zoster virus (VZV) strain Ellen to acyclovir in combination with other antiherpetic agents in vitro has been examined by the plaque-reduction and infectious center assay methods."( Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro.
Biron, KK; Elion, GB, 1982
)
0.26
"Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC refractory to standard therapies."( Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020
)
0.56
" Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC."( Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020
)
0.56
"TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI)."( TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Aprile, G; Cianchi, F; Fancelli, S; Gatta Michelet, MR; Lavacchi, D; Mini, E; Nobili, S; Roviello, F; Roviello, G, 2020
)
0.78
" The favorable safety profile of trifluridine/tipiracil renders it a suitable option to be combined with other local therapies for metastatic lesions."( Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Lin, BR; Lin, YL; Liu, KL, 2020
)
2.28
"The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
2.4
"Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
3.61
"We conducted a phase I study to evaluate the maximum tolerated dose (MTD), safety, and efficacy of trametinib in combination with TAS-102 in patients with chemotherapy-refractory KRAS-mutant, wild-type PIK3CA/PTEN metastatic colorectal cancer (mCRC)."( A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C, 2022
)
0.72
"Trametinib in combination with TAS-102 demonstrated a manageable safety profile."( A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C, 2022
)
0.72
" A Phase 1, 2-part (dose escalation, dose expansion), non-randomized, open-label, first-in-human study of CA102N, as monotherapy and in combination with trifluridine-tipiracil, was conducted in patients with locally advanced or metastatic solid tumors."( Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023
)
1.32
"From October 2020 to February 2022, patients with metastatic colorectal cancer who failed from 2 or more lines of prior therapy and treated with TAS-102 monotherapy, in combination with bevacizumab or immune checkpoint inhibitors (ICIs) were analyzed."( An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023
)
1.24
" Furthermore, the effect of using TAS-102 in combination with CTS was studied in xenograft tumor nude mice model."( Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer.
Chen, ZM; Han, WX; Luo, PQ; Wang, G; Wei, ZJ; Xu, AM; Ying, S; Zhang, LX; Zhu, H, 2023
)
1.21
" Our mechanism studies indicate that FTD could block HGC-27 cells at G2/M phase, while CTS could block HGC-27 cells at G1/G0 phase, while FTD combined with CTS could mainly block HGC-27 cells at G2 phase."( Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer.
Chen, ZM; Han, WX; Luo, PQ; Wang, G; Wei, ZJ; Xu, AM; Ying, S; Zhang, LX; Zhu, H, 2023
)
1.21

Bioavailability

TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride. Maximum concentrations of both drugs decreased by approximately 40%.

ExcerptReferenceRelevance
" In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI."( Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K, 2004
)
0.32
" TFT is a good substrate for thymidine phosphorylase (TP), and the combination of TFT and a TP inhibitor (TPI), called TAS-102, has been developed to enhance the bioavailability of TFT in vivo, and is currently being studied in a phase I study."( Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells.
Comijn, EM; de Bruin, M; Fukushima, M; Peters, GJ; Temmink, OH, 2005
)
0.33
" The pyrimidine analog trifluorothymidine (TFT) is part of the anti-cancer drug formulation TAS-102, which was developed to enhance the bioavailability of TFT in vivo, and is currently being evaluated as an oral chemotherapeutic agent in phase I clinical studies."( Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
Fukushima, M; Hoebe, EK; Peters, GJ; Temmink, OH, 2007
)
0.34
" The pyrimidine analog trifluorothymidine (TFT) forms together with a thymidine phosphorylase inhibitor (TPI) the anticancer drug formulation TAS-102, in which TPI enhances the bioavailability of TFT in vivo."( Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Ackland, SP; Fukushima, M; Hoebe, EK; Peters, GJ; Temmink, OH; van der Born, K, 2007
)
0.34
" The thymidine analog trifluorothymidine (TFT) has been shown to bypass resistance pathways for 5FU derivatives (S-1, UFT, Xeloda) in model systems, while concurrent application with a thymidine phosphorylase inhibitor (TPI) increases the bioavailability of TFT, thereby potentiating the in vivo efficacy of TFT."( Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
de Bruin, M; Emura, T; Fukushima, M; Peters, GJ; Temmink, OH, 2007
)
0.34
" TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD."( TAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz, HJ; Loupakis, F; Stintzing, S, 2015
)
0.67
" TPI is an inhibitor of TFD degradation enzyme thymidine phosphorylase and thus increases the bioavailability of TFD."( TAS-102 an Emerging Oral Fluoropyrimidine.
Chen, J; Han, M; Saif, MW, 2016
)
0.43
" Maximum concentrations of both drugs decreased by approximately 40%, indicating that food influenced the absorption and bioavailability of trifluridine and tipiracil hydrochloride, respectively."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.64
" The rapid degradation of TFT brought initial clinical development to a halt, but TFT reentered clinical trials when addition of a TPI was found to improve the bioavailability of TFT."( TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
Opdam, FL; van der Velden, DL; Voest, EE, 2016
)
0.43
" It is a combination of two active pharmaceutical compounds, trifluridine, an antineoplastic thymidine-based nucleoside analog, and tipiracil, which enhances the bioavailability of trifluridine in vivo."( Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T, 2016
)
0.91
" A phase 1 study evaluated relative bioavailability of TAS-102 tablets compared with an oral solution containing equivalent amounts of FTD and TPI."( A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
Becerra, CR; Mizuguchi, H; Patel, M; Von Hoff, D; Yoshida, K, 2017
)
0.67
" Tipiracil blocks the degradation of trifluridine by thymidine phosphorylase, which improves the bioavailability of trifluridine and allows for oral administration."( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
1.08
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine."( First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020
)
2.39
"Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine."( Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
Amellal, N; Ciardiello, F; Fakih, M; Fougeray, R; Leger, C; Prager, GW; Tabernero, J; Taieb, J; van Cutsem, E, 2021
)
3.51

Dosage Studied

ExcerptRelevanceReference
" The short-timed high dosage of F3TDR seems to have no delaying effect on epithelial regeneration."( [Epithel regeneration inhibition in the treatment of Trifluorothymidin (F3TDR) (author's transl)].
Holtmann, HW; Stein, HJ, 1977
)
0.26
" In fact, the divided dosing of CF3dUrd to L1210-bearing mice was markedly more effective than its single administration."( Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound.
Hayatsu, H; Matsumoto, H; Satake, H; Takeda, S; Unemi, N; Wataya, Y; Wierzba, K; Yamada, Y; Yamashita, J, 1992
)
0.28
" At the lower doses, the dose-response curve was linear, with no indication of a threshold."( Toxicity and mutagenicity of low dose rates of ionizing radiation from tritiated water in human lymphoblastoid cells.
Liber, HL; Little, JB; Ozaki, VH, 1985
)
0.27
" A parallel 19F NMR spectroscopic study was also performed on rats dosed with F3TdR, to observe the qualitative pattern of F3TdR metabolism in another species."( alpha-Trifluoromethyl-beta-alanyl glycine (F3MBAG): a novel mammalian metabolite of trifluridine (F3TdR).
Kumar, P; Tandon, M; Wiebe, LI, 1994
)
0.51
" It was used for the in vivo testing and showed antiviral efficacy in a dose-dependent manner, and at dosing four times a day, it was of comparable efficacy to trifluorothymidine (nine times a day)."( Efficacy of polyclonal antibodies for treatment of ocular herpes simplex infection.
Asbell, PA; Epstein, SP; Nurozler, M; Smetana, CR, 2001
)
0.31
" The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily."( Management of acyclovir-resistant herpes simplex virus.
Chilukuri, S; Rosen, T, 2003
)
0.32
" When TAS-102 was administered into tumor-bearing mice once daily or three times daily at 3-h intervals at a dose of 150 mg/kg/day for one or 3 consecutive days, incorporation of FTD into tumor DNA by divided dosing significantly higher than that of single dosing."( An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
Emura, T; Fujioka, A; Kitazato, K; Nakagawa, F; Ohshimo, H; Okabe, H; Yokogawa, T, 2004
)
0.32
" However, the optimal duration and dosage of antiviral prevention have yet to be defined."( [The latest in herpes simplex keratitis therapy].
Labetoulle, M, 2004
)
0.32
" Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition."( A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004
)
0.32
"This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors."( Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Abbruzzese, JL; Fukushima, M; Hoff, PM; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Thomas, MB; Varadhachary, G; Wolff, RA; Xiong, H, 2008
)
0.35
" Six of 16 patients (37%) receiving long-term oral acyclovir had recurrent HSV, at least one case of which followed a growth spurt that caused the baseline dosage of acyclovir to become subtherapeutic."( Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes.
Colby, KA; Liu, S; Pavan-Langston, D, 2012
)
0.38
" Oral acyclovir is effective, but the dosage must be adjusted as the child grows."( Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes.
Colby, KA; Liu, S; Pavan-Langston, D, 2012
)
0.38
" Moreover, we recommend that, for patients with repeated treatment postponement due to neutropenia, the dosage should be fixed based on therapeutic efficacy and prognosis."( Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016
)
0.71
" It can be postulated that the dosage of TAS-102 potentially may need to be increased to achieve better outcomes in patients not experiencing any neutropenia."( Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T, 2016
)
0.43
" This Phase I, open-label, nonrandomized study investigated the safety, tolerability and pharmacokinetics of FTD/TPI in patients with advanced solid tumours (except breast cancer) and varying degrees of hepatic impairment, to provide dosing recommendations."( Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019
)
0.81
"Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)."( A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019
)
0.51
"8%) had dosing modifications because of adverse events vs 101 (53."( Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E, 2020
)
0.87
" The patient received several courses of chemotherapy with adjustments of the dose and dosing intervals to prevent neutropenia."( [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021
)
0.62
"The optimum dosing strategy for regorafenib has improved its benefit-to-toxicity ratio and relative cost-effectiveness compared to RSD, TAS-102, and TAS-BEV."( Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US.
Babajanyan, S; Barzi, A; Bekaii-Saab, T; Cho, SK; Hocum, B; Kavati, A, 2022
)
0.72
"In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure."( Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023
)
1.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
EC 2.1.1.45 (thymidylate synthase) inhibitorAn EC 2.1.1.* (methyltransferases) inhibitor that interferes with the action of thymidylate synthase (EC 2.1.1.45).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
pyrimidine 2'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency2.23870.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency100.00000.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency2.90930.004110.890331.5287AID504467
Fumarate hydrataseHomo sapiens (human)Potency11.22020.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency0.19910.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency15.84650.000714.592883.7951AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency13.33320.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency6.68240.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.00000.01237.983543.2770AID1346984
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.95910.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency0.10590.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.43900.000229.305416,493.5996AID743069; AID743078; AID743079
polyproteinZika virusPotency11.22020.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency0.69630.00018.4406100.0000AID720579; AID720580
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.86760.001019.414170.9645AID743094; AID743191
IDH1Homo sapiens (human)Potency1.83560.005210.865235.4813AID686970
Histone H2A.xCricetulus griseus (Chinese hamster)Potency0.32570.039147.5451146.8240AID1224845; AID1224896
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency11.22021.000012.232631.6228AID1452
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency10.32250.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency8.76760.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency33.48890.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.89550.000627.21521,122.0200AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency1.63600.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency12.58930.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency1.99530.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency4.07120.002319.595674.0614AID651631; AID720552
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency4.48040.009610.525035.4813AID1479145; AID1479148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase Macacine alphaherpesvirus 1IC50 (µMol)2.00000.15002.57504.2000AID326127
exodeoxyribonuclease V subunit RecBEscherichia coli str. K-12 substr. MG1655IC50 (µMol)92.26850.10000.10000.1000AID492957; AID652151
exodeoxyribonuclease V subunit RecCEscherichia coli str. K-12 substr. MG1655IC50 (µMol)92.26850.10000.10000.1000AID492957; AID652151
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Thymidylate kinaseMycobacterium tuberculosis H37RvKi97.00004.50008.500010.0000AID210904
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LMP1 [Human herpesvirus 4]human gammaherpesvirus 4 (Epstein-Barr virus)AC501.31800.068039.9389277.4300AID504882; AID588398
Thymidylate synthaseMus musculus (house mouse)ID500.03500.03500.03500.0350AID212649
Thymidine phosphorylaseHomo sapiens (human)Km798.00000.16000.16000.1600AID211066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (157)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitochondrial genome maintenanceThymidine phosphorylaseHomo sapiens (human)
angiogenesisThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleobase metabolic processThymidine phosphorylaseHomo sapiens (human)
pyrimidine nucleoside metabolic processThymidine phosphorylaseHomo sapiens (human)
chemotaxisThymidine phosphorylaseHomo sapiens (human)
signal transductionThymidine phosphorylaseHomo sapiens (human)
cell differentiationThymidine phosphorylaseHomo sapiens (human)
regulation of myelinationThymidine phosphorylaseHomo sapiens (human)
dTMP catabolic processThymidine phosphorylaseHomo sapiens (human)
regulation of transmission of nerve impulseThymidine phosphorylaseHomo sapiens (human)
regulation of gastric motilityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
1,4-alpha-oligoglucan phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein bindingThymidine phosphorylaseHomo sapiens (human)
growth factor activityThymidine phosphorylaseHomo sapiens (human)
thymidine phosphorylase activityThymidine phosphorylaseHomo sapiens (human)
protein homodimerization activityThymidine phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
cytosolThymidine phosphorylaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (142)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID84072Compound was evaluated for antiviral activity against HSV-1(strain KOS)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID527285Cytotoxicity against human HuH7 cells2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID220992Evaluation of antitumor activity against thymidine kinase deficient Raji cell line1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID87826Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain 196.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID517830Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID326137Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID98529Evaluation of antitumor activity against mutant murine leukemia L1210 cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID517842Cytotoxicity against HuH7 cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1145911Cytotoxicity against mouse Sarcoma 180 cells after 1 to 3 days by coulter counter analysis1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis and biological activities of 5-trifluoromethyl-5'-azido-2',5'-dideoxyuridine and 5-trifluoromethyl-5'-amino-2',5'-dideoxyuridine.
AID517837Antiviral activity against drug resistant HBV infected in M204I cells assessed as inhibition of viral DNA replication2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID87508Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain McIntyre1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID326127Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID128180Antitumor activity against transplanted tumor sarcoma 180 expressed as effective dose.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Studies on antitumor agents. 8. Antitumor activities of O-alkyl derivatives of 2'-deoxy-5-(trifluoromethyl)uridine and 2'-deoxy-5-fluorouridine.
AID210904Inhibitory activity against thymidine monophosphate kinase (TMPK) in Mycobacterium tuberculosis2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
AID165523Concentration of compound required to inhibit [1',2'-3H]dUrd incorporation into host cell DNA by 50% in primary rabbit kidney cell cultures1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID517827Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication at 1 ug/ml2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID326131Activity of Herpes B virus recombinant thymidine kinase at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID87507Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain KOS.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID326134Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID326138Cytotoxicity against african green monkey Vero cells after 2 days2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID82317Growth inhibition against HL-60 after 48 hours incubation period1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID1145906Antiviral activity against HSV1 CL-101 infected in African green monkey Vero cells assessed as reduction of viral titer at 50 uM after 40 hrs1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis and biological activities of 5-trifluoromethyl-5'-azido-2',5'-dideoxyuridine and 5-trifluoromethyl-5'-amino-2',5'-dideoxyuridine.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID84953Compound was evaluated for antiviral activity against HSV-2(strain G)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID527283Antiviral activity against HBV infected in human 2.2.15 cell at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID216539Evaluation of antiviral activity against Vesicular stomatitis virus.1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID517838Antiviral activity against drug resistant HBV infected in M204I cells assessed as inhibition of viral DNA replication at 10 ug/mL2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID1135481Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID527281Antiviral activity against HBV infected in duck primary hepatocytes at 10 ug/ml2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus.
AID218174In vitro percent inhibition of replication of vero cells at 1 uM concentration1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and biological activity of 5-(trifluoromethyl)- and 5-(pentafluoroethyl)pyrimidine nucleoside analogues.
AID681387TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID87828Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain Lyons1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID232840Ratio of Vmax to that of dThd (Vmax = 0.14)1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID517831Antiviral activity against HBV assessed as inhibition of viral DNA replication2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID211066Michaelis-Menten constant (Km) against horse liver thymidine phosphorylase1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Thymidine phosphorylase. Substrate specificity for 5-substituted 2'-deoxyuridines.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID326135Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1135479Antiviral activity against Herpes simplex virus 1 infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID82323The compound was tested for [3H]TdR incorporation into DNA in HL-60 cells1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145909Cytotoxicity against African green monkey Vero cells at 1 uM after 3 days by haemocytometer analysis1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Synthesis and biological activities of 5-trifluoromethyl-5'-azido-2',5'-dideoxyuridine and 5-trifluoromethyl-5'-amino-2',5'-dideoxyuridine.
AID87506Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain F1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID87827Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID218132Evaluation of antiviral activity against Vaccinia virus1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID212649The compound was tested for inhibition of thymidylate synthase (TS) in L1210 cells1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID326136Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID165524Concentration of compound required to inhibit [methyl-3H]dThd incorporation into host cell DNA by 50% in primary rabbit kidney cell cultures1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID84759Effective dose required for antiherpes activity against HSV-2(G) strain1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID517832Antiviral activity against HBV assessed as inhibition of viral DNA replication at 10 ug/mL2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID1135478Antiviral activity against Vaccinia virus infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID681766TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Trifluridine: 1000 uM) in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
AID1135480Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID198962In vitro percent inhibition of replication of S-180 cells at 0.1 uM concentration1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and biological activity of 5-(trifluoromethyl)- and 5-(pentafluoroethyl)pyrimidine nucleoside analogues.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID82318Growth inhibition against HL-60 after 72 hours incubation period1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID84071Compound was evaluated for antiviral activity against HSV-1(TK-, strain B2006)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID217982Compound was evaluated for antiviral activity against vaccinia1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (E)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1.
AID218175In vitro percent inhibition of replication of vero cells at 10 uM concentration1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and biological activity of 5-(trifluoromethyl)- and 5-(pentafluoroethyl)pyrimidine nucleoside analogues.
AID221339Evaluation for antitumor activity against human lymphoblast Raji cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID82316Growth inhibition against HL-60 after 24 hours incubation period1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID85711Effective dose required for antiherpes activity against HSV-1(F) strain1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
AID517826Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication at 10 ug/ml2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and
AID98532Evaluation of cytostatic activity by using antitumor assays against murine leukemia L1210 cells1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2'-deoxyuridine 3',5'-cyclic monophosphates and neutral triesters.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (723)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990221 (30.57)18.7374
1990's82 (11.34)18.2507
2000's57 (7.88)29.6817
2010's180 (24.90)24.3611
2020's183 (25.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 72.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index72.32 (24.57)
Research Supply Index6.77 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index128.03 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (72.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials121 (16.22%)5.53%
Reviews83 (11.13%)6.00%
Case Studies64 (8.58%)4.05%
Observational14 (1.88%)0.25%
Other464 (62.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (71)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Open-Label, Multicenter Trial of Sym004 Versus Trifluridine/Tipiracil (TAS-102) in Patients With Chemotherapy-Refractory or Relapsed Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR Monoclonal Antibody Therapy [NCT03717038]Phase 30 participants (Actual)Interventional2019-02-28Withdrawn(stopped due to Study was withdrawn due to administrative reasons)
Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotec [NCT05201352]Phase 1/Phase 2160 participants (Anticipated)Interventional2022-03-31Not yet recruiting
A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers [NCT03368963]Phase 1/Phase 264 participants (Anticipated)Interventional2018-01-30Recruiting
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer [NCT03317119]Phase 126 participants (Anticipated)Interventional2018-04-11Active, not recruiting
Efficacy and Safety of Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy for Refractory Metastatic Colorectal Cancer: a Retrospective Study [NCT05869097]90 participants (Actual)Observational2020-11-01Completed
An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 [NCT02743221]Phase 2154 participants (Actual)Interventional2016-04-29Completed
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherap [NCT04894123]Phase 21 participants (Actual)Interventional2022-02-07Terminated(stopped due to Recruitment failure)
An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT) [NCT03306394]Phase 3907 participants (Actual)Interventional2016-10-18Completed
A Non-interventional Study to Assess Effectiveness and Safety of Trifluridin/Tipiracil in Patients With Metastatic Colorectal Cancer [NCT03665506]315 participants (Actual)Observational2018-06-25Completed
A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment [NCT04776148]Phase 3480 participants (Actual)Interventional2021-03-29Active, not recruiting
A Multi-Centre, Open-Label Phase 2 Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (The MOCHA Trial) [NCT04076761]Phase 28 participants (Actual)Interventional2019-12-11Terminated(stopped due to Lack of Funding)
A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors [NCT04393298]Phase 1/Phase 295 participants (Actual)Interventional2020-07-09Active, not recruiting
A Single-arm, Phase II Clinical Trial to Treat Locally Advanced, pMMR Rectal Cancer With Single-agent Trifluridine/Tipiracil Chemotherapy Plus Neoadjuvant Intensity-modulated Radiotherapy [NCT05965531]Phase 265 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC: A Retrospective Cohort Study Based on Propensity Score Matching [NCT06031376]106 participants (Actual)Observational2019-07-01Completed
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study [NCT04260269]200 participants (Anticipated)Observational2018-06-01Enrolling by invitation
Single-Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients Under Fasting or Postprandial Conditions [NCT03974594]Phase 164 participants (Actual)Interventional2019-05-21Completed
3T: A Phase II Single Arm Open Label Study of Tucatinib Combined With Trastuzumab and TAS-102 in Molecularly Selected Patients With HER2+ Metastatic Colorectal Cancer [NCT05356897]Phase 230 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE) [NCT04104139]Phase 118 participants (Anticipated)Interventional2019-12-11Recruiting
An Open-label, Phase II Investigation of TAS-102 in Patients With High Grade, Extrapulmonary Neuroendocrine Carcinoma [NCT04042714]Phase 214 participants (Anticipated)Interventional2019-08-15Recruiting
Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA) [NCT04280536]Phase 1/Phase 286 participants (Anticipated)Interventional2019-08-14Recruiting
A Retrospective Observational Study of Trifluridine/ Tipiracil (TAS-102) in Chemorefractory Metastatic Colorectal Cancer (mCRC) in Greece. Real World Data on Clinical Benefit. [NCT04965870]200 participants (Actual)Observational2021-06-30Completed
Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal Cancer [NCT02848443]Phase 178 participants (Actual)Interventional2016-05-31Completed
TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy [NCT05343013]Phase 215 participants (Anticipated)Interventional2022-06-06Recruiting
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study [NCT04660760]Phase 2116 participants (Anticipated)Interventional2021-06-16Recruiting
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer [NCT05328908]Phase 3700 participants (Anticipated)Interventional2022-04-28Recruiting
A Randomized, Controlled, Multicenter Phase II Trial of Regorafenib Combined With Trifluridine/Tipiracil Versus Regorafenib Monotherapy in Patients With Metastatic Colorectal Cancer Who Failed at Least Two Lines of Systematic Therapy [NCT05970705]Phase 2101 participants (Anticipated)Interventional2023-07-01Recruiting
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study). [NCT05927857]Phase 1/Phase 245 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer [NCT04073615]Phase 1/Phase 229 participants (Actual)Interventional2019-11-18Completed
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment of Stage III and High-risk Stage II Resected Colon Cancer Patients With Adjuvant FOLFOXIRI and/or Post-adjuvant Trifluridine/Tipiracil [NCT05062889]Phase 2477 participants (Anticipated)Interventional2023-05-17Recruiting
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects Wit [NCT05198934]Phase 3160 participants (Actual)Interventional2022-04-19Active, not recruiting
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) [NCT04879368]Phase 3450 participants (Anticipated)Interventional2021-06-01Recruiting
A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients [NCT04564898]Phase 1/Phase 248 participants (Anticipated)Interventional2022-01-25Recruiting
Phase Ib Open-Label Study to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of Multiple Subcutaneous Injections of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to TAS-102 in Late-Stage Metastatic Colorectal Cancer Subjects [NCT05130060]Phase 115 participants (Actual)Interventional2022-01-10Completed
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations [NCT04854434]Phase 213 participants (Actual)Interventional2021-06-29Terminated(stopped due to Sponsor decision)
A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone [NCT01867866]Phase 144 participants (Actual)Interventional2013-05-31Completed
A Randomised, Open-label, Multi-centre, Two-arm Phase 3 Study Comparing Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil to Trifluridine/Tipiracil Single Agent With a Safety Lead-In Part in Participants With KRAS/NRAS and BRAF Wild Type Me [NCT05223673]Phase 37 participants (Actual)Interventional2022-04-21Terminated(stopped due to Decision based on strategic reasons related to limited development options left in metastatic colorectal cancer.)
Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer: FIRE-8; AIO-KRK/YMO-05 [NCT05007132]Phase 2153 participants (Anticipated)Interventional2021-12-17Recruiting
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer [NCT03992456]Phase 284 participants (Anticipated)Interventional2020-04-24Active, not recruiting
TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer [NCT04294264]Phase 250 participants (Anticipated)Interventional2019-02-12Active, not recruiting
An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study) [NCT04737187]Phase 3492 participants (Actual)Interventional2020-11-25Completed
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine [NCT00000635]25 participants InterventionalCompleted
Use of Trifluridine/Tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma [NCT04097028]Phase 222 participants (Actual)Interventional2019-12-20Active, not recruiting
A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer [NCT04457297]Phase 3240 participants (Anticipated)Interventional2020-07-08Recruiting
Phase 1,Two-part (Dose Escalation, Dose Expansion), Multicenter,Non-randomized,Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors [NCT03616574]Phase 137 participants (Actual)Interventional2019-04-09Completed
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial [NCT04177602]Phase 1/Phase 210 participants (Actual)Interventional2019-11-04Terminated(stopped due to Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer the study to the phase II part, as superiority over standard chemoradiation and transfer to a new therapy standard are increasingly unlikely.)
Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for T [NCT05476796]Phase 2118 participants (Anticipated)Interventional2023-06-23Recruiting
An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candida [NCT03869892]Phase 3856 participants (Actual)Interventional2019-03-21Active, not recruiting
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers [NCT03981614]Phase 2102 participants (Actual)Interventional2019-10-29Active, not recruiting
A Randomized Study Evaluating Tailoring of Advanced/Metastatic Colorectal Cancer (CRC) Therapy Using Circulating Cell-Free Tumor DNA (ctDNA) (TACT-D) [NCT03844620]Phase 2100 participants (Actual)Interventional2019-01-29Active, not recruiting
Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer [NCT03297710]Phase 17 participants (Actual)Interventional2017-12-11Completed
Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study [NCT00002037]15 participants InterventionalCompleted
A Phase 2 Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer [NCT04149444]Phase 20 participants (Actual)Interventional2020-02-29Withdrawn(stopped due to Sponsor withdrew support)
A Phase 2, Randomized, Open Label Study to Evaluate Efficacy, Safety, and Tolerability of CA102N Combined With Trifluridine/Tipiracil (TAS-102) Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer (mCRC) Who Failed t [NCT06039202]Phase 2100 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Prospective, Open, Single-center, Single-arm Study to Explore Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of mCRC Patients Who Were Refractory to Second-line and Above Standard Therapy. [NCT06060704]Phase 233 participants (Anticipated)Interventional2023-11-30Recruiting
A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer [NCT03031691]Phase 17 participants (Actual)Interventional2017-01-31Completed
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial [NCT05468892]Phase 268 participants (Actual)Interventional2019-10-29Completed
Open, Non Controlled, Parallel Cohorts, Multicenter, Phase 2A Study for Evaluation of the Antitumor Activity of GM102 Single Agent and in Combination With Chemotherapy in Patients With Locally Advanced Or Metastatic Colorectal Cancer [NCT03799731]Phase 265 participants (Actual)Interventional2018-07-11Completed
A Study to Evaluate the Safety and Feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102), and Oxaliplatin (iTTo) for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [NCT04808791]Phase 220 participants (Anticipated)Interventional2021-08-31Not yet recruiting
Open-label Phase II Study With Lead-in Safety Cohort of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) Combination Treatment in Patients With Previously Treated Advanced Gastric Cancer [NCT05508737]Phase 1/Phase 275 participants (Anticipated)Interventional2022-12-01Not yet recruiting
A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients [NCT01896856]Phase 1/Phase 2118 participants (Actual)Interventional2013-10-23Completed
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO) [NCT04109924]Phase 242 participants (Actual)Interventional2019-12-27Active, not recruiting
A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) [NCT04868773]Phase 112 participants (Anticipated)Interventional2021-07-16Active, not recruiting
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer [NCT04450836]Phase 2340 participants (Anticipated)Interventional2020-11-23Recruiting
Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer [NCT03223779]Phase 1/Phase 256 participants (Anticipated)Interventional2017-10-13Recruiting
A Phase 2 Study of Trifluridine/Tipiracil in Patients With ER-positive, HER2-negative Advanced Breast Cancer That Previously Received Chemotherapy [NCT04489173]Phase 250 participants (Anticipated)Interventional2020-09-25Recruiting
(STAR-T) Sequential TreAtment With Regorafenib and Trifluridine/Tipiracil (TAS-102, With or Without Bevacizumab) in Refractory Metastatic Colorectal Cancer: Real-world Outcomes in Community Clinical Practice in the USA [NCT05839951]818 participants (Actual)Observational2023-04-24Active, not recruiting
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers [NCT03278106]Phase 228 participants (Actual)Interventional2017-10-20Completed
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy [NCT04166604]Phase 2250 participants (Anticipated)Interventional2020-05-20Recruiting
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers [NCT04072445]Phase 228 participants (Actual)Interventional2019-10-18Completed
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer (TOBACO): a Randomized, Controlled, Phase II Study [NCT05077839]Phase 2184 participants (Anticipated)Interventional2021-09-01Recruiting
A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers [NCT04511039]Phase 141 participants (Anticipated)Interventional2021-06-08Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01896856 (4) [back to overview]Progression Free Survival (PFS)
NCT01896856 (4) [back to overview]Overall Survival
NCT01896856 (4) [back to overview]Objective Response Rate
NCT01896856 (4) [back to overview]Number of Participants Experiencing a Dose Limiting Toxicity
NCT02743221 (5) [back to overview]Disease Control Rate (DCR)
NCT02743221 (5) [back to overview]Duration of Response (DR)
NCT02743221 (5) [back to overview]Overall Response Rate (ORR)
NCT02743221 (5) [back to overview]Overall Survival (OS)
NCT02743221 (5) [back to overview]Progression Free Survival (PFS)
NCT03278106 (5) [back to overview]Overall Survival (OS)
NCT03278106 (5) [back to overview]Overall Response Rate (ORR)
NCT03278106 (5) [back to overview]16-Week Progression-free Survival (PFS) Rate
NCT03278106 (5) [back to overview]Progression-free Survival (PFS)
NCT03278106 (5) [back to overview]Overall Toxicity Rates (Percentages) for Grade 3 or Higher Adverse Events Considered at Least Possibly Related to Treatment, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)
NCT03981614 (4) [back to overview]Progression Free Survival (PFS)
NCT03981614 (4) [back to overview]Overall Response Rate
NCT03981614 (4) [back to overview]Number of Participants With Adverse Events
NCT03981614 (4) [back to overview]Overall Survival (OS)
NCT04072445 (6) [back to overview]Disease Control Rate (DCR)
NCT04072445 (6) [back to overview]Overall Response Rate (ORR)
NCT04072445 (6) [back to overview]Overall Survival (OS)
NCT04072445 (6) [back to overview]PFS
NCT04072445 (6) [back to overview]Progression-free Survival (PFS)
NCT04072445 (6) [back to overview]Number of Participants With Adverse Events
NCT04737187 (9) [back to overview]Probability of Participants With Progression Free Survival at 3, 6, 9 and 12 Months
NCT04737187 (9) [back to overview]Survival Probability at 6 Months
NCT04737187 (9) [back to overview]Overall Response Rate (ORR)
NCT04737187 (9) [back to overview]Percentage of Participants With Disease Control
NCT04737187 (9) [back to overview]Progression Free Survival (PFS)
NCT04737187 (9) [back to overview]Survival Probability at 12 Months
NCT04737187 (9) [back to overview]Survival Probability at 18 Months
NCT04737187 (9) [back to overview]Overall Survival (OS)
NCT04737187 (9) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)
NCT04854434 (11) [back to overview]Arm A, B and C: Overall Survival (OS)
NCT04854434 (11) [back to overview]Arm A and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1
NCT04854434 (11) [back to overview]Arm A and C: Overall Response Rate (ORR)
NCT04854434 (11) [back to overview]Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
NCT04854434 (11) [back to overview]Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
NCT04854434 (11) [back to overview]Arm A and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1
NCT04854434 (11) [back to overview]Arm B and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1
NCT04854434 (11) [back to overview]Arm B and C: Overall Response Rate (ORR)
NCT04854434 (11) [back to overview]Arm A, B and C: Progression-free Survival (PFS) at 6 Months
NCT04854434 (11) [back to overview]Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 6 Months
NCT04854434 (11) [back to overview]Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 12 Months

Progression Free Survival (PFS)

Progression Free Survival is the time (in months) from start of treatment to progression, clinical deterioration attributed to disease, or death. (NCT01896856)
Timeframe: Up to 12 months

Interventionmonths (Median)
Phase 2: Arm A SGI-110 + Irinotecan2.37
Phase 2: Arm B Regorafenib or TAS-1022.09

[back to top]

Overall Survival

Overall Survival is defined as the time (in months) between the start of treatment and death. (NCT01896856)
Timeframe: Up to 3 years

Interventionmonths (Median)
Phase 2: Arm A SGI-110 + Irinotecan7.15
Phase 2: Arm B Regorafenib or TAS-1027.66

[back to top]

Objective Response Rate

Objective Response Rate (ORR) is defined as the number of subjects achieving a Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. CR = disappearance of all target lesions, PR = at least 30% decrease in the sum of diameters of target lesions. (NCT01896856)
Timeframe: Assessed until disease progression, up to 3 years

InterventionParticipants (Count of Participants)
Phase 2: Arm A SGI-110 + Irinotecan1
Phase 2: Arm B Regorafenib or TAS-1020

[back to top]

Number of Participants Experiencing a Dose Limiting Toxicity

"Number of participants experiencing a Dose Limiting Toxicity (DLT) in each dose level. DLT is defined as any of the following study drug-related toxicities occurring during the first cycle of study drug on study:~grade 4 thrombocytopenia lasting >7days~any grade 3-4 febrile neutropenia~grade 3 or higher non-hematologic toxicity unless it could be managed by supportive treatment~any other clinically significant adverse event which would place subjects at undue safety risk, or results in discontinuation of treatment." (NCT01896856)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Dose Level 11
Dose Level -12
Dose Level -1G1
Dose Level 1G1

[back to top]

Disease Control Rate (DCR)

DCR was the proportion of patients with confirmed CR, PR or stable disease (SD) as best overall response. SD defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)

InterventionParticipants (Count of Participants)
Trifluridine/Tipiracil + Bevacizumab66
Capecitabine + Bevacizumab59

[back to top]

Duration of Response (DR)

The DR was calculated among patients with CR or PR as the time (months) from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 16.6 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab7.9
Capecitabine + Bevacizumab9.9

[back to top]

Overall Response Rate (ORR)

As per RECIST v1.1, Complete Response (CR) was disappearance of all target lesions; Partial Response (PR) was at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The ORR was the proportion of patients who presented CR or PR with confirmation at subsequent time point or at least 4 weeks later. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)

InterventionParticipants (Count of Participants)
Trifluridine/Tipiracil + Bevacizumab26
Capecitabine + Bevacizumab23

[back to top]

Overall Survival (OS)

The OS was defined as the time from the date of randomisation to the date of death. If death was not confirmed, or patient was alive at study cut-off date, survival time was censored at the date of last follow-up or at the study cut-off date, whichever was earlier. (NCT02743221)
Timeframe: Baseline up to death or study cut-off (maximum follow-up duration: 19.9 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab18.0
Capecitabine + Bevacizumab16.2

[back to top]

Progression Free Survival (PFS)

The progression free survival (PFS), defined as the time from the date of randomisation until the date of the investigator-assessed radiological disease progression or death due to any cause according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive disease (PD) was defined at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and an absolute increase of at least 5 mm in the sum of lesions or the appearance of new lesions. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab9.2
Capecitabine + Bevacizumab7.8

[back to top]

Overall Survival (OS)

OS will be estimated using the Kaplan-Meier method. OS is defined as the time from study entry to death from any cause. Patients will be censored at the date patient was last known to be alive. The median OS and 95% confidence interval will be reported. (NCT03278106)
Timeframe: Time from study entry to death from any cause, assessed up to 3 years

Interventionmonths (Median)
Treatment (TAS-102)6.1

[back to top]

Overall Response Rate (ORR)

ORR defined as the percentage of patients who experience either a partial response or complete response by the given time point. Complete Response (CR):All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to <1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the BSD. (NCT03278106)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
Treatment (TAS-102)0

[back to top]

16-Week Progression-free Survival (PFS) Rate

16-Week Progression-free survival (PFS) rate is defined as the percentage of patients who are progression-free (stable disease, partial response, or complete response as defined by RECIST v1.1 criteria) at 16 weeks post registration. (NCT03278106)
Timeframe: 16 weeks

Interventionpercentage of patients (Number)
Treatment (TAS-102)32.0

[back to top]

Progression-free Survival (PFS)

PFS will be estimated using the Kaplan-Meier method. Progression-Free Survival (PFS) is defined as the time from study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on RECIST 1.1 criteria. Patients will be censored at the last disease assessment date. The median PFS and 95% confidence interval will be reported. (NCT03278106)
Timeframe: Time from study entry to the first of either disease progression or death from any cause, assessed up to 3 years

Interventionmonths (Median)
Treatment (TAS-102)3.8

[back to top] [back to top]

Progression Free Survival (PFS)

Disease progression will be determined based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and will be documented at each enrolling site with no central review planned. PFS will be compared between treatment arms using the stratified log rank test at one-sided level 0.05. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. (NCT03981614)
Timeframe: Time from randomization date to either disease progression or death from any cause, whichever occurs first, assessed for up to 16 months

Interventionmonths (Median)
Arm A (Binimetinib, Palbociclib)2.3
Arm B (Trifluridine and Tipiracil Hydrochloride)2.2

[back to top]

Overall Response Rate

Assessment of response data will be performed on the basis of definitions of responses according to RECIST version (v)1.1. Objective response is defined as a complete or partial response by RECIST v1.1. This will be reported as the number of patients experiencing an objective response. (NCT03981614)
Timeframe: Up to 16 months

InterventionParticipants (Count of Participants)
Arm A (Binimetinib, Palbociclib)0
Arm B (Trifluridine and Tipiracil Hydrochloride)1

[back to top]

Number of Participants With Adverse Events

The number of patients experiencing a grade 3+ adverse event, regardless of attribution, will be reported. (NCT03981614)
Timeframe: Up to 24 months

InterventionParticipants (Count of Participants)
Arm A (Binimetinib, Palbociclib)25
Arm B (Trifluridine and Tipiracil Hydrochloride)28
Safety Run-In Cohort6

[back to top]

Overall Survival (OS)

Will use Kaplan-Meier methods to evaluate time to event endpoints, and will report median OS and its 95% confidence interval. (NCT03981614)
Timeframe: Time from first dose of study treatment to death from any cause, assessed for up to 24 months

Interventionmonths (Median)
Arm A (Binimetinib, Palbociclib)7.7
Arm B (Trifluridine and Tipiracil Hydrochloride)6.8

[back to top]

Disease Control Rate (DCR)

Will be defined as the proportion of patients who experience a partial response, complete response, or have stable disease as their best response. DCR will be reported descriptively and a 95% confidence interval will be reported. (NCT04072445)
Timeframe: Up to 20 months

Interventionpercentage of participants (Number)
Treatment (Trifluridine and Tipiracil, Irinotecan)50

[back to top]

Overall Response Rate (ORR)

Will be defined as the proportion of patients who experience either a partial response or complete response as their best response. ORR will be reported descriptively and a 95% confidence interval will be reported. (NCT04072445)
Timeframe: Up to 20 months

Interventionpercentage of participants (Number)
Treatment (Trifluridine and Tipiracil, Irinotecan)20.0

[back to top]

Overall Survival (OS)

Will be estimated using the Kaplan-Meier method. The median OS and 95% confidence interval will be reported. Patients will be censored at the date patient was last known to be alive. (NCT04072445)
Timeframe: From study entry to death from any cause, assessed up to 20 months

Interventionmonths (Median)
Treatment (Trifluridine and Tipiracil, Irinotecan)9.1

[back to top]

PFS

Will be determined based on RECIST v 1.1. PFS will be estimated using the Kaplan-Meier method. The median PFS and 95% confidence interval will be reported. Patients will be censored at the last disease assessment date. (NCT04072445)
Timeframe: From study entry to the first of either disease progression or death from any cause, assessed up to 20 months

Interventionmonths (Median)
Treatment (Trifluridine and Tipiracil, Irinotecan)3.9

[back to top]

Progression-free Survival (PFS)

Will be defined as the proportion of evaluable patients who are progression-free (stable disease, partial response, complete response) at 16 weeks and assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. Confidence intervals for the true success proportion will be calculated according to the approach of Clopper and Pearson. (NCT04072445)
Timeframe: Up to 16 weeks

Interventionpercentage of participants (Number)
Treatment (Trifluridine and Tipiracil, Irinotecan)37.0

[back to top]

Number of Participants With Adverse Events

The maximum grade for each type of adverse event by patient will be summarized by frequencies and percentages using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. (NCT04072445)
Timeframe: Up to 28 days

InterventionParticipants (Count of Participants)
Grade 3+ AEGrade 4 AEGrade 5 AE
Treatment (Trifluridine and Tipiracil, Irinotecan)2040

[back to top]

Probability of Participants With Progression Free Survival at 3, 6, 9 and 12 Months

PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. In this outcome measure, data of PFS at 3 months was reported. (NCT04737187)
Timeframe: From randomization until 3, 6, 9, and 12 months post treatment

,
Interventionprobability of participants (Number)
At 3 MonthsAt 6 MonthsAt 9 MonthsAt 12 Months
Trifluridine/Tipiracil0.450.160.050.01
Trifluridine/Tipiracil + Bevacizumab0.730.430.280.16

[back to top]

Survival Probability at 6 Months

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 6 months was reported. (NCT04737187)
Timeframe: From date of randomization until 6 months post treatment

Interventionprobability of participants (Number)
Trifluridine/Tipiracil + Bevacizumab0.77
Trifluridine/Tipiracil0.61

[back to top]

Overall Response Rate (ORR)

Objective response was defined as percentage of participants who achieved complete response (CR) or partial response (PR) according to the RECIST version 1.1 and using investigator's tumour assessment. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. (NCT04737187)
Timeframe: From the date of randomization to the date of documentation of progression or death due to any cause or data cut-off, whichever occurred first (i.e., up to 20 months)

Interventionpercentage of participants (Number)
Trifluridine/Tipiracil + Bevacizumab6.10
Trifluridine/Tipiracil1.22

[back to top]

Percentage of Participants With Disease Control

Disease control is defined as percentage of participants who achieved CR or PR, or stable disease (SD) as per RECIST 1.1 and using investigator's tumour assessment from the date of randomization to until disease progression or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. (NCT04737187)
Timeframe: From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)

Interventionpercentage of participants (Number)
Trifluridine/Tipiracil + Bevacizumab69.51
Trifluridine/Tipiracil41.87

[back to top]

Progression Free Survival (PFS)

PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. (NCT04737187)
Timeframe: From randomization to the date of radiological tumour progression or death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab5.55
Trifluridine/Tipiracil2.40

[back to top]

Survival Probability at 12 Months

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 12 months was reported. (NCT04737187)
Timeframe: From date of randomization until 12 months post treatment

Interventionprobability of participants (Number)
Trifluridine/Tipiracil + Bevacizumab0.43
Trifluridine/Tipiracil0.30

[back to top]

Survival Probability at 18 Months

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 18 months was reported. (NCT04737187)
Timeframe: From date of randomization until 18 months post treatment

Interventionprobability of participants (Number)
Trifluridine/Tipiracil + Bevacizumab0.28
Trifluridine/Tipiracil0.15

[back to top]

Overall Survival (OS)

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. (NCT04737187)
Timeframe: From date of randomization to the death due to any cause or cut-ff date, whichever comes first (maximum duration: up to 20 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab10.78
Trifluridine/Tipiracil7.46

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs. (NCT04737187)
Timeframe: From Baseline up to 30 days after the last dose of study treatments (i.e., up to 19.5 months)

,
InterventionParticipants (Count of Participants)
TEAETESAE
Trifluridine/Tipiracil24177
Trifluridine/Tipiracil + Bevacizumab24161

[back to top]

Arm A, B and C: Overall Survival (OS)

OS was defined as time from the date of randomization to death due to any cause. (NCT04854434)
Timeframe: From the date of randomization up to death (up to 8 months)

Interventionmonths (Median)
Arm A: Selinexor 80 mgNA
Arm B: Selinexor 80 mg and Pembrolizumab 400 mgNA
Arm C: Standard of Care (SOC)NA

[back to top]

Arm A and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1

Disease control rate was defined as participants who achieved best overall response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as assessed by investigator as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study. (NCT04854434)
Timeframe: From the date of randomization up to death (up to 8 months)

Interventionpercentage of participants (Number)
Arm A: Selinexor 80 mg100

[back to top]

Arm A and C: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieve CR or PR or or initiating a new antineoplastic therapy. ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT04854434)
Timeframe: From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 8 months)

Interventionpercentage of participants (Number)
Arm A: Selinexor 80 mg25.0
Arm C: Standard of Care (SOC)0

[back to top]

Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

PFS was defined as the time from the date of randomization until disease progression or death due to any cause, whichever occurs first. PFS was assessed by the investigator per RECIST 1.1. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions. (NCT04854434)
Timeframe: From the date of randomization until disease progression or death, whichever occurs first (up to 8 months)

InterventionMonths (Median)
Arm B: Selinexor 80 mg and Pembrolizumab 400 mgNA
Arm C: Standard of Care (SOC)NA

[back to top]

Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs. (NCT04854434)
Timeframe: From start of study drug administration up to 12 months

,,
InterventionParticipants (Count of Participants)
Participants with TEAEsParticipants with Serious TEAEs
Arm A: Selinexor 80 mg41
Arm B: Selinexor 80 mg and Pembrolizumab 400 mg52
Arm C: Standard of Care (SOC)40

[back to top]

Arm A and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1

DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT04854434)
Timeframe: From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 8 months)

Interventionmonths (Median)
Arm A: Selinexor 80 mgNA

[back to top]

Arm B and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1

Disease control rate was defined as participants who achieved best overall response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as assessed by investigator as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study. (NCT04854434)
Timeframe: From the date of randomization up to death (up to 8 months)

Interventionpercentage of participants (Number)
Arm B: Selinexor 80 mg and Pembrolizumab 400 mg40.0

[back to top]

Arm B and C: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieve complete response (CR) or partial response (PR) or or initiating a new antineoplastic therapy. ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT04854434)
Timeframe: From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 8 months)

Interventionpercentage of participants (Number)
Arm B: Selinexor 80 mg and Pembrolizumab 400 mg0
Arm C: Standard of Care (SOC)0

[back to top]

Arm A, B and C: Progression-free Survival (PFS) at 6 Months

PFS at 6 months was defined as the time from the date of randomization without disease progression at 6 months as assessed by the investigator per RECIST 1.1. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. (NCT04854434)
Timeframe: At 6 Months

Interventionmonths (Median)
Arm A: Selinexor 80 mgNA
Arm B: Selinexor 80 mg and Pembrolizumab 400 mgNA
Arm C: Standard of Care (SOC)NA

[back to top]

Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 6 Months

OS was defined as the time from the first dose date to date of death due to any cause. Participant was considered as event (overall survival) free if participant was not died and was alive at 6 months. (NCT04854434)
Timeframe: At 6 Months

Interventionpercentage of event free participants (Median)
Arm A: Selinexor 80 mgNA
Arm B: Selinexor 80 mg and Pembrolizumab 400 mgNA
Arm C: Standard of Care (SOC)NA

[back to top]

Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 12 Months

OS was defined as the time from the first dose date to date of death due to any cause. Participant was considered as event (overall survival) free if participant was not died and was alive at 12 months. (NCT04854434)
Timeframe: At 12 Months

Interventionpercentage of event free participants (Median)
Arm A: Selinexor 80 mgNA
Arm B: Selinexor 80 mg and Pembrolizumab 400 mgNA
Arm C: Standard of Care (SOC)NA

[back to top]